Sea Limited vs State Street SPDR S&P Biotech ETF — how do they compare? Sea Limited trades at $106.01 (market cap $64.73B), while State Street SPDR S&P Biotech ETF trades at $154.43. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals.
| SE | XBI | |
|---|---|---|
Market Cap | $64.73B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $196.50 | $164.28 |
52-Week Low | $78.16 | $85.16 |
Enterprise Value | $57.78B | — |
Signals from Pluang's Aura AI — not financial advice
Sea Limited (SE) trades at $106.26, up 2.12% with a neutral technical signal. The company shows strong revenue growth, reaching $22.94 billion in 2025 with a net income margin of 6.36%. Recent earnings beat expectations in Q1 2026 but missed in prior quarters. Analyst sentiment remains bullish with a $131 consensus price target, though insider selling has drawn attention amid a 30% stock decline over the past year.
The outlook is mixed: robust fundamentals and analyst support suggest upside potential, but risks include earnings volatility, competitive pressures, and geopolitical factors affecting sentiment. The stock's valuation at a P/E of 41.61 requires sustained growth to justify current levels, making execution critical for future performance.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →